Boston Pharmaceuticals
CompanyUnited StatesFounded 2015
Boston Pharmaceuticals develops one asset, in phase 3 (Efimosfermin Alfa in metabolic dysfunction-associated steatohepatitis). Mostly protein or enzyme; based in the United States, founded in 2015.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 4
- Signals
Pipeline
1FGF21 receptor agonist analog regulating lipid metabolism and reducing liver fibrosis
Phase 3, Protein or enzyme, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals16
- Integrity notices1
- Similar companies6